In metastatic breast cancer, ctDNA assays can non-invasively determine tumor genetics such as PIK3CA and ESR1 mutation status, which direct the use of targeted therapies (PI3K inhibitors like alpelisib for PIK3CA-mutant tumors, or novel endocrine therapies for ESR1-mutant cases). This evidence concerns the gene ESR1 and neoplasm.